On Monday, Cue Biopharma Inc (NASDAQ: CUE) was 8.72% up from the session before settling in for the closing price of $1.72. A 52-week range for CUE has been $0.45 – $3.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 163.36%. When this article was written, the company’s average yearly earnings per share was at 37.16%. With a float of $59.65 million, this company’s outstanding shares have now reached $60.21 million.
Let’s determine the extent of company efficiency that accounts for 53 employees. In terms of profitability, gross margin is 58.74%, operating margin of -580.34%, and the pretax margin is -566.02%.
Cue Biopharma Inc (CUE) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cue Biopharma Inc stocks. The insider ownership of Cue Biopharma Inc is 0.92%, while institutional ownership is 27.53%.
Cue Biopharma Inc (CUE) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.24 earnings per share (EPS) during the time that was better than consensus figure (set at -0.34) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.16% per share during the next fiscal year.
Cue Biopharma Inc (NASDAQ: CUE) Trading Performance Indicators
You can see what Cue Biopharma Inc (CUE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.06. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.97, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Cue Biopharma Inc (CUE)
Looking closely at Cue Biopharma Inc (NASDAQ: CUE), its last 5-days average volume was 0.78 million, which is a jump from its year-to-date volume of 0.45 million. As of the previous 9 days, the stock’s Stochastic %D was 72.90%. Additionally, its Average True Range was 0.25.
During the past 100 days, Cue Biopharma Inc’s (CUE) raw stochastic average was set at 92.26%, which indicates a significant increase from 82.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 122.93% in the past 14 days, which was lower than the 147.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0707, while its 200-day Moving Average is $1.4223. However, in the short run, Cue Biopharma Inc’s stock first resistance to watch stands at $2.0094. Second resistance stands at $2.1488. The third major resistance level sits at $2.3085. If the price goes on to break the first support level at $1.7103, it is likely to go to the next support level at $1.5506. Now, if the price goes above the second support level, the third support stands at $1.4112.
Cue Biopharma Inc (NASDAQ: CUE) Key Stats
There are 48,643K outstanding shares of the company, which has a market capitalization of 108.80 million. As of now, sales total 5,490 K while income totals -50,730 K. Its latest quarter income was 2,660 K while its last quarter net income were -10,170 K.
